Cantor Fitzgerald initiated coverage of Evommune (EVMN) with an Overweight rating. The firm is “very bullish” on EVO756 for chronic spontaneous urticaria, citing a “differentiated” mechanism annd first-in-class potential. The positive data in chronic inducible urticaria meaningfully increases the probability of success for the CSU trial, the analyst tells investors in a research note. Cantor sees a “very attractive” risk/reward at current share levels for Evommune’s atopic dermatitis readouts in 2026.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVMN:
- Evommune initiated with an Outperform at Evercore ISI
- Evommune initiated with an Outperform at William Blair
- Promising Outlook for Evommune’s EVO756: Buy Rating Backed by Strong Data and Market Potential
- Evommune initiated with an Overweight at Morgan Stanley
- Promising Future for Evommune, Inc. in Inflammatory and Immunology Markets: Buy Rating Justified by Strong Pipeline and Experienced Leadership